Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung

• Main Authors: WETZEL, ANNE, ANDEREGG, ULF, SAALBACH, ANJA
• Format: Patent
• Language: German
• Published: 03.12.2009
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

Antibody (I), which specifically recognizes human thiamine 1 (Thy-1) (CD90), for blocking the binding of human Thy-1 at its ligand, is new. Independent claims are also included for: (1) (I) obtained from hybridoma-cell line with the deposit number of DSM ACC2690; (2) hybridoma-cell line with the deposit number DSM ACC2690; (3) preparation of monoclonal antibodies against human Thy-1 comprising immunising BALB/c mice with human Thy-1, fusing its spleen cells, selecting the antibody producing hybridoma in a selective medium, cloning and far increasing the reactive and specific hybridoma by cultivation, where hybridoma-cell line with the deposit number DSM ACC2690 is used for cultivation and antibody production; (4) immunological test kit comprising at least (I) or a product derived from it; and (5) pharmaceutical preparation comprising (I) or a product derived from it. ACTIVITY : Cytostatic; Antiarthritic; Antiinflammatory; Antipsoriatic; Antirheumatic. No biological data given. MECHANISM OF ACTION : None given.